stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Revenue
BioCryst Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $874.8M, up 94.1% from $450.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $961.5M. Over the past ten years it has ranged from $17.8M (fiscal 2020) to $874.8M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. BioCryst Pharmaceuticals, Inc. ranks 22nd of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $874.8M | 94.10% |
| FY2024 | $450.7M | 36.00% |
| FY2023 | $331.4M | 22.37% |
| FY2022 | $270.8M | 72.31% |
| FY2021 | $157.2M | 782.38% |
| FY2020 | $17.8M | (63.53%) |
| FY2019 | $48.8M | 136.45% |
| FY2018 | $20.7M | (18.00%) |
| FY2017 | $25.2M | (4.43%) |
| FY2016 | $26.4M | (45.39%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $180.3M | (17.39%) |
| Jun 2026 | $218.3M | 39.53% |
| Mar 2026 | $156.4M | (61.53%) |
| Dec 2025 | $406.6M | 155.06% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| ANIP ANI Pharmaceuticals, Inc. compare | $1.0B |
| BCRX BioCryst Pharmaceuticals, Inc. | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. compare | $368.3M |
| ALVO Alvotech compare | $293.3M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BCRX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement